These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For research use only.  Legal & Disclaimer

Regulatory Reference · Research Use Only

503A vs. 503B Compounding —
What Peptide Researchers and Practitioners Need to Know

A clear breakdown of the two compounding frameworks, where research peptide suppliers fit, and what the FDA's 503A bulk substances list means for your practice.

General information only. The content on this page is provided for educational and informational purposes. It does not constitute legal, regulatory, or medical advice. The compounding pharmacy regulatory landscape changes frequently — consult qualified legal and compliance counsel for guidance specific to your practice or facility.

Section 1

The Two Compounding Frameworks

U.S. pharmaceutical compounding operates under two distinct statutory frameworks created by the Drug Quality and Security Act (DQSA) of 2013. Understanding the difference is essential for any practitioner, med spa, or clinic working with compounded formulations.

Characteristic 503A
Traditional Compounding		 503B
Outsourcing Facility
Prescription Requirement Patient-specific prescription required for each compound Can compound without patient-specific prescriptions — batch compounding permitted
Primary Regulatory Authority State pharmacy boards (with federal oversight floor) Federal FDA oversight; registered and inspected by FDA
Manufacturing Standards USP standards; not subject to full cGMP Current Good Manufacturing Practice (cGMP) standards required
Bulk Drug Substances May use bulk drug substances on the FDA-maintained 503A bulk substances list (with conditions) May use bulk drug substances on the FDA 503B bulks list (separate, more limited list)
Volume Capability Generally lower volume; patient-specific batches Higher volume capability; designed for large-scale production
Typical Examples Small compounding pharmacies, specialty pharmacies serving specific patients FDA-registered outsourcing facilities supplying hospitals, clinics, and practitioners at scale
Key Distinguishing Factor Must have a valid, patient-specific prescription for each preparation FDA-registered, inspected, cGMP compliant; can hold office stock

Both frameworks serve legitimate functions in the healthcare system. 503A pharmacies focus on individualized patient care; 503B outsourcing facilities enable broader institutional access at scale. Neither framework applies to research peptide suppliers like Sequence Labs — which operates under a separate, distinct framework.

Section 2

Where Research Peptide Suppliers Fit

Research peptide suppliers occupy a distinct regulatory category that is separate from both 503A and 503B compounding. Understanding this distinction protects practitioners and ensures that supply chain decisions are made with accurate information.

Research Use Only (RUO) Framework
Sequence Labs operates under the Research Use Only (RUO) framework — a separate regulatory category for compounds supplied strictly for laboratory research, pre-clinical study, and investigational purposes. RUO suppliers do not sell to end-use patients and do not operate as compounding pharmacies. Compounds are supplied to licensed practitioners and qualified researchers who evaluate them for research applications.
The Practitioner's Role in the Supply Chain
Licensed practitioners who purchase from RUO suppliers like Sequence Labs may independently work with 503A compounding pharmacies for patient-specific formulations. These are two distinct, separate relationships — the RUO supplier does not compound for patients and is not part of the 503A transaction chain.

The typical supply chain for practitioners working at the intersection of research and clinical care:

These relationships are legally and operationally distinct. Sequence Labs provides research compounds and documentation — it does not prescribe, dispense for patient use, or hold itself out as a compounding pharmacy under either framework.

Section 3

The 503A Bulk Substances List

The FDA maintains a list of bulk drug substances that 503A pharmacies are permitted to use for compounding. This list — formally part of the agency's implementation of Section 503A of the FD&C Act — directly determines which peptide compounds can be compounded for patients at traditional compounding pharmacies.

Inclusion on, removal from, or re-listing on this catalog has significant downstream consequences: a substance removed from the 503A bulks list cannot legally be used by a 503A pharmacy to compound a patient-specific formulation, regardless of what research on that compound shows.

Regulatory Updates — 2025–2026
Recent & Upcoming Actions Affecting Peptide Access
  • In Effect
    14 Peptides Restored (Early 2026): HHS under Secretary RFK Jr. restored access to 14 research peptides that had been under restriction, reversing prior FDA enforcement actions. This materially expanded what 503A pharmacies may compound in certain categories.
  • July 23, 2026
    Thymosin Alpha-1 — FDA Advisory Committee: An FDA advisory committee review of Thymosin Alpha-1 is scheduled for July 23, 2026. The outcome of this review will directly affect whether Thymosin Alpha-1 remains accessible for 503A compounding. Practitioners who incorporate this compound in their research programs should monitor this proceeding closely.
  • Ongoing
    Regulatory Monitoring Program: Sequence Labs monitors FDA, DEA, and HHS regulatory actions affecting research peptides daily. B2B clients receive direct alerts when material changes occur that may affect their research programs or sourcing decisions.

The 503A bulk substances list is a living regulatory document. What is permitted today may be restricted tomorrow — and what has been restricted may be restored. Practitioners who depend on compounded peptide formulations benefit from working with research suppliers who monitor this space continuously.

Section 4

What This Means for Med Spas

Med spas operating at the intersection of aesthetic and functional medicine increasingly rely on compounded formulations as part of their service offerings. Navigating this regulatory environment requires understanding both where your compounding pharmacy fits and where your upstream research supplier fits.

Regulatory Landscape Awareness
Med spas working with compounding pharmacies need research suppliers who understand the 503A/503B framework — not suppliers who treat regulatory context as an afterthought. Sequence Labs' team includes PA-C and DEA-registered practitioner oversight, creating compliance alignment throughout the supply relationship.
COA Documentation for Quality Systems
Sequence Labs' batch-specific COAs from Krause Analytical (Austin, TX) provide the purity, identity, and potency documentation that compounding pharmacies require for their own quality systems. All COAs are publicly verifiable via Finnrick Pulse — not available only on internal request.
Real-Time Regulatory Monitoring
The 503A bulk substances list changes without notice to practitioners. Sequence Labs' regulatory monitoring program tracks FDA and DEA actions affecting research peptides daily, alerting B2B clients to material changes before they affect sourcing or clinical programming decisions.
B2B Program Built for Clinics
Sequence Labs' wholesale program is specifically designed for med spa and clinic supply chains — with tiered pricing, gated account access, and direct support for practitioners establishing research protocols. No one-size-fits-all retail experience.

Frequently Asked Questions

Yes — licensed medical practitioners and med spas with appropriate professional credentials can establish wholesale accounts with Sequence Labs. Accounts are reviewed by our PA-C and require verification of professional credentials. Contact Team@SequenceLabs.Health to initiate a wholesale inquiry.
The FDA 503A bulk substances list specifies which compounds traditional compounding pharmacies are permitted to use when preparing patient-specific formulations. A compound must appear on this list (or meet other specific criteria) for a 503A pharmacy to compound it legally. Changes to this list — additions, removals, or temporary restrictions — directly affect which peptides can be compounded for patients. Sequence Labs monitors this list continuously and notifies B2B clients of changes relevant to their research programs.
Batch-specific Certificates of Analysis (COAs) from Krause Analytical (Austin, TX) provide independent third-party documentation of purity, identity, and potency using HPLC and mass spectrometry verification. Compounding pharmacies conducting their own quality assessments or working to satisfy state pharmacy board documentation requirements benefit from this level of specificity and verifiability. All Sequence Labs COAs are publicly accessible via Finnrick Pulse — not gated behind sales processes.
In early 2026, HHS under Secretary RFK Jr. reversed prior FDA restrictions and restored access to 14 research peptides that had been placed under restriction. This represented a significant shift in the regulatory landscape for practitioners and compounding pharmacies. The environment continues to evolve — including an upcoming FDA advisory committee review of Thymosin Alpha-1 scheduled for July 23, 2026. Sequence Labs' regulatory monitoring program tracks FDA and DEA actions daily and alerts clients to material changes that may affect their research or sourcing decisions.
No. Sequence Labs is a Research Use Only (RUO) supplier — a distinct regulatory category from both 503A and 503B compounding. We supply research compounds to licensed practitioners and qualified researchers. We are not a pharmacy, do not dispense to patients, and do not compound patient-specific formulations. Practitioners who work with us may separately engage 503A compounding pharmacies for patient-facing formulations — these are independent, separate relationships.

Partner with a Supplier Who Understands the Landscape

Sequence Labs' B2B program is designed for med spas and practitioners who need more than a catalog — regulatory awareness, documentation quality, and direct practitioner support.

Apply for Wholesale Account View Full Catalog